Table 1 Clinical characteristics of patients

Patients, n

25

24

Median age, years (range)

64.0 (60–73)

64.1 (60–71)

Gender, n

 Male

12

10

 Female

13

14

FAB subtypes, n

 M0-M1

3

2

 M2

11

12

 M4

5

4

 M5

4

5

 M6-M7

2

1

AML, de novo

23

23

Secondary to MDS

2

1

ECOG

 0–1

24

22

  ≥ 2

1

2

HCT-CI score

 0

11

10

 1/2

12

10

  ≥ 3

2

4

ELN 2017 risk classification, n

 Favorable

5

4

 Intermediate

14

15

 Adverse

6

4

Molecular aberrant, n/Na

14/25

17/24

 FLT3-ITD

1

2

 FLT3-TKD

1

1

 NPM1

5

7

 DNMT3A

3

2

 CEBPA

3

6

 AML-ETO

2

1

 MLL

3

1

 N-RAS

1

2

MRD to induction, n

  ≤ 0. 1%

13

13

  > 0. 1%

12

11

Neutrophils≥0.5 × 10⁹/L, d, median (range)

11.9 (0–19)

15.3 (2–26)

Platelet ≥20 × 10⁹/L, d, median (range)

11.5 (8–18)

18.8 (11–28)